File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Long-term combination therapy with aspirin and clopidogrel
  • Basic View
  • Metadata View
  • XML View
TitleLong-term combination therapy with aspirin and clopidogrel
 
AuthorsKumana, CR1
Cheung, G1
Lauder, IJ1
Cheung, BMY1
 
KeywordsChemicals And Cas Registry Numbers
 
Issue Date2004
 
PublisherSage Publications, Inc. The Journal's web site is located at http://cpt.sagepub.com
 
CitationJournal Of Cardiovascular Pharmacology And Therapeutics, 2004, v. 9 n. 4, p. 223-225 [How to Cite?]
DOI: http://dx.doi.org/10.1177/107424840400900402
 
AbstractThe possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies. To assess the overall absolute beneficial and/or harmful impact of aspirin and clopidogrel combination therapy compared with monotherapy with either drug, we analyzed the results from both trials in terms of number needed to treat per year. Treating between 35 and 204 at-risk patients for 1 year with combination therapy appeared to prevent 1 patient from experiencing an adverse primary cardiovascular outcome; whereas, about 1 in 63 such patients appeared liable to major bleeding during that period. We determined that the evidence to date indicates no overall advantage for combination therapy with anti-platelet drugs in preference to monotherapy.
 
ISSN1074-2484
2013 Impact Factor: 3.072
2013 SCImago Journal Rankings: 1.276
 
DOIhttp://dx.doi.org/10.1177/107424840400900402
 
ISI Accession Number IDWOS:000226495700002
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorKumana, CR
 
dc.contributor.authorCheung, G
 
dc.contributor.authorLauder, IJ
 
dc.contributor.authorCheung, BMY
 
dc.date.accessioned2010-09-17T10:23:00Z
 
dc.date.available2010-09-17T10:23:00Z
 
dc.date.issued2004
 
dc.description.abstractThe possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies. To assess the overall absolute beneficial and/or harmful impact of aspirin and clopidogrel combination therapy compared with monotherapy with either drug, we analyzed the results from both trials in terms of number needed to treat per year. Treating between 35 and 204 at-risk patients for 1 year with combination therapy appeared to prevent 1 patient from experiencing an adverse primary cardiovascular outcome; whereas, about 1 in 63 such patients appeared liable to major bleeding during that period. We determined that the evidence to date indicates no overall advantage for combination therapy with anti-platelet drugs in preference to monotherapy.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Cardiovascular Pharmacology And Therapeutics, 2004, v. 9 n. 4, p. 223-225 [How to Cite?]
DOI: http://dx.doi.org/10.1177/107424840400900402
 
dc.identifier.doihttp://dx.doi.org/10.1177/107424840400900402
 
dc.identifier.epage225
 
dc.identifier.isiWOS:000226495700002
 
dc.identifier.issn1074-2484
2013 Impact Factor: 3.072
2013 SCImago Journal Rankings: 1.276
 
dc.identifier.issue4
 
dc.identifier.pmid15678241
 
dc.identifier.scopuseid_2-s2.0-12344307601
 
dc.identifier.spage223
 
dc.identifier.urihttp://hdl.handle.net/10722/91664
 
dc.identifier.volume9
 
dc.languageeng
 
dc.publisherSage Publications, Inc. The Journal's web site is located at http://cpt.sagepub.com
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Cardiovascular Pharmacology and Therapeutics
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAngina, Unstable - drug therapy
 
dc.subject.meshArteriosclerosis - drug therapy
 
dc.subject.meshAspirin - administration & dosage - adverse effects - therapeutic use
 
dc.subject.meshCyclooxygenase Inhibitors - administration & dosage - adverse effects - therapeutic use
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshDrug Administration Schedule
 
dc.subject.meshDrug Therapy, Combination
 
dc.subject.meshHumans
 
dc.subject.meshPlacebos
 
dc.subject.meshPlatelet Aggregation Inhibitors - administration & dosage - adverse effects - therapeutic use
 
dc.subject.meshRandomized Controlled Trials as Topic
 
dc.subject.meshRecurrence
 
dc.subject.meshThrombosis - drug therapy
 
dc.subject.meshTiclopidine - administration & dosage - adverse effects - analogs & derivatives - therapeutic use
 
dc.subject.meshTreatment Outcome
 
dc.subjectChemicals And Cas Registry Numbers
 
dc.titleLong-term combination therapy with aspirin and clopidogrel
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Kumana, CR</contributor.author>
<contributor.author>Cheung, G</contributor.author>
<contributor.author>Lauder, IJ</contributor.author>
<contributor.author>Cheung, BMY</contributor.author>
<date.accessioned>2010-09-17T10:23:00Z</date.accessioned>
<date.available>2010-09-17T10:23:00Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>Journal Of Cardiovascular Pharmacology And Therapeutics, 2004, v. 9 n. 4, p. 223-225</identifier.citation>
<identifier.issn>1074-2484</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/91664</identifier.uri>
<description.abstract>The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies. To assess the overall absolute beneficial and/or harmful impact of aspirin and clopidogrel combination therapy compared with monotherapy with either drug, we analyzed the results from both trials in terms of number needed to treat per year. Treating between 35 and 204 at-risk patients for 1 year with combination therapy appeared to prevent 1 patient from experiencing an adverse primary cardiovascular outcome; whereas, about 1 in 63 such patients appeared liable to major bleeding during that period. We determined that the evidence to date indicates no overall advantage for combination therapy with anti-platelet drugs in preference to monotherapy.</description.abstract>
<language>eng</language>
<publisher>Sage Publications, Inc. The Journal&apos;s web site is located at http://cpt.sagepub.com</publisher>
<relation.ispartof>Journal of Cardiovascular Pharmacology and Therapeutics</relation.ispartof>
<subject>Chemicals And Cas Registry Numbers</subject>
<subject.mesh>Angina, Unstable - drug therapy</subject.mesh>
<subject.mesh>Arteriosclerosis - drug therapy</subject.mesh>
<subject.mesh>Aspirin - administration &amp; dosage - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Cyclooxygenase Inhibitors - administration &amp; dosage - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Drug Administration Schedule</subject.mesh>
<subject.mesh>Drug Therapy, Combination</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Placebos</subject.mesh>
<subject.mesh>Platelet Aggregation Inhibitors - administration &amp; dosage - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Randomized Controlled Trials as Topic</subject.mesh>
<subject.mesh>Recurrence</subject.mesh>
<subject.mesh>Thrombosis - drug therapy</subject.mesh>
<subject.mesh>Ticlopidine - administration &amp; dosage - adverse effects - analogs &amp; derivatives - therapeutic use</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Long-term combination therapy with aspirin and clopidogrel</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1177/107424840400900402</identifier.doi>
<identifier.pmid>15678241</identifier.pmid>
<identifier.scopus>eid_2-s2.0-12344307601</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-12344307601&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>9</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>223</identifier.spage>
<identifier.epage>225</identifier.epage>
<identifier.isi>WOS:000226495700002</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong